Why primary care hesitates, and why the story is less about one hormone than about sport, scandal, a decade-long heart scare, and clinics that made saying yes look like the problem.

The short version
- Testosterone is the only common replacement hormone that is also a Schedule III controlled substance and a banned doping drug. Thyroid hormone, insulin and estrogen are not controlled substances. Estrogen is expressly excluded from the anabolic-steroid definition in US law.
- A 2013 to 2014 cardiovascular scare drove prescribing down 48% in established users and 62% in new users between 2013 and 2016, on the strength of observational studies and a meta-analysis, not a randomized safety trial.
- TRAVERSE (2023, n=5,246) found testosterone gel noninferior to placebo for major cardiovascular events (7.0% vs 7.3%; HR 0.96). In February 2025 the FDA removed the boxed warning on cardiovascular risk, and added a blood-pressure warning at the same time.
- The guidelines never banned testosterone. They require symptoms plus two low early-morning levels, a search for the cause, and monitoring. Much of the reluctance is about everything around the prescription, not the molecule alone.
The drug with three identities
Ask a primary care doctor to replace thyroid hormone and nobody blinks. Levothyroxine is deficiency medicine: measure, replace, recheck. Insulin is the same. Estrogen, for all its own controversies, is prescribed as hormone therapy. Testosterone should sit in that same row, a hormone, replaced when it is genuinely low, monitored like any other.
It does not sit in that row. Testosterone is the only common replacement hormone that carries three identities at once: medicine, crime, and cheating. It is a legitimate treatment for hypogonadism. It is also a Schedule III controlled substance under the US Controlled Substances Act, regulated by the DEA in the same tier as ketamine and codeine combination products, a category defined by accepted medical use alongside potential for abuse. And it is the archetypal doping drug, the substance behind stripped medals and fallen champions.
That triple identity is not rhetoric. It is written into the statute itself. Federal law defines an anabolic steroid as any drug or hormonal substance “chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth” (21 U.S.C. §802). The definition is built around testosterone, and estrogen is carved out of it by name. Thyroid hormone and insulin were never in it at all.
So a clinician who prescribes testosterone is, in regulatory terms, prescribing a drug of abuse, from a DEA-registered practice, for a documented legitimate medical purpose, on a prescription that expires in six months. Possession without a prescription is a federal crime. No other hormone on the shelf asks the prescriber to work inside that frame. Clinicians absorbed the framing along with the pharmacology: this is the hormone you defend, not the hormone you simply replace.
Every other replacement hormone is treated as deficiency medicine. Testosterone alone arrives at the visit with a criminal record and a doping scandal attached.
One honest limit before going further: no study found in the research for this article directly measured how much of today’s reluctance the legal history caused. The link is inferential. The law made the drug symbolically different, and practice culture followed. What is documented is the law, the scare that followed, and the measurable collapse in prescribing when that scare peaked. Those come next.
How sport made a hormone a controlled substance
Synthetic testosterone was isolated and synthesized in 1935 and used medically for decades, for hypogonadism, delayed puberty, some anaemias and some breast cancers, long before anyone scheduled it. The drug predates its criminalization by 55 years. What changed was not the medicine. What changed was sport.
A medicine first
Testosterone is isolated and synthesized. For the next five decades it is a prescription medicine for defined deficiencies, not a federally controlled substance.
Seoul, and the scandal era
Ben Johnson is stripped of Olympic gold at the 1988 Seoul Games after testing positive for a steroid. Congressional hearings follow in 1988 to 1990. The stated objective of the legislation that follows is to remove steroids from competitive sport and from cosmetic and bodybuilding use, not to regulate endocrinology.
Anabolic Steroids Control Act of 1990
Enacted 29 November 1990 as part of the Crime Control Act (Pub. L. 101 to 647), effective 27 February 1991. Anabolic steroids, originally 27 compounds, defined around testosterone, are placed in Schedule III. Non-medical use and distribution are criminalized.
The net widens
After the BALCO scandal, the Anabolic Steroid Control Act of 2004 (signed 22 October 2004, effective 20 January 2005) broadens the definition to capture designer steroids and prohormone precursors such as androstenedione sold as supplements. Sources disagree on the expanded list’s exact count, 49 versus 59 named substances, so no precise count is claimed here.
Designer Anabolic Steroid Control Act
About two dozen further designer steroids are added, with new offences for false labeling. The framework built for sport now fully surrounds a hormone doctors had prescribed since the 1930s.
There is a contested footnote worth flagging rather than repeating as fact. Multiple secondary histories report that the AMA, FDA, DEA, NIDA and NIH testified against scheduling in 1988 to 1990, arguing anabolic steroids did not meet the Controlled Substances Act’s dependence criterion, and that Congress proceeded anyway to “send a message.” That account appears in secondary and partisan sources; it was not verified against a primary hearing record in the research for this article, so treat it as a widely repeated claim, not an established one.
What needs no caveat is the direction of travel. A hormone became a controlled substance because of what athletes and bodybuilders did with it. Every prescriber since has inherited that decision, including the ones seeing a 58-year-old with two low morning levels and a textbook symptom picture, who has never been near a podium or a stage.
The cardiovascular scare, 2013 to 2015
If the law gave testosterone its reputation, the years 2013 to 2015 gave primary care its reason. Three publications, none of them a randomized safety trial, raised the possibility that testosterone therapy increased heart attacks, strokes and death. The FDA responded, labels changed, and prescribing fell off a cliff.
On 31 January 2014, the FDA issued a Drug Safety Communication announcing it was evaluating the risk of stroke, heart attack and death with approved testosterone products. That September, an FDA advisory committee voted 20 to 1 to restrict the indicated population and require a cardiovascular safety trial. On 3 March 2015, the FDA required label changes: testosterone was approved only for men with low testosterone caused by certain medical conditions; benefit and safety for low testosterone due to aging were not established; and labels had to carry information about a possible increased risk of heart attack and stroke. The FDA’s own wording was careful, “possible” with some studies showing risk and others not. In practice, careful wording rarely survives contact with a busy clinic. What survived was the warning.
Vigen et al., JAMA 2013
Design: Retrospective national VA cohort of 8,709 men with total testosterone <300 ng/dL who had coronary angiography (2005 to 2011); 1,223 started testosterone.
Finding: Composite of death, MI and ischaemic stroke at 3 years: 25.7% (testosterone) vs 19.9% (no testosterone) on Kaplan, Meier estimates; adjusted HR 1.29 (95% CI 1.04 to 1.58).
Limit: Retrospective and not randomized. Who gets treated, and why, cannot be separated from the result. Critics noted the raw event count was lower in the treated group (123/1,223, 10.1% vs 1,587/7,486, 21.2%) and that the headline figures were model-based estimates; JAMA issued corrections. The claim that the study is therefore “reversed” is itself contested.
Finkle et al., PLoS One 2014
Design: Claims-database cohort of 55,593 men with a first testosterone prescription, comparing non-fatal MI in the 90 days after the prescription with the prior year.
Finding: Post/pre rate ratio 1.36 (95% CI 1.03 to 1.81). In men ≥65, RR 2.19; in men <65, excess risk appeared only with prior heart disease (RR 2.90).
Limit: The paper itself lists them: no data on indication, labs, race or lifestyle; no data on how much drug was actually taken; non-fatal MI only. In absolute terms the increase was small, about 1 additional MI per 1,000 person-years (3.48 to 4.75) in secondary analyses.
Xu et al., BMC Medicine 2013
Design: 27 placebo-controlled trials, 2,994 mainly older men, 180 cardiovascular-related events in total.
Finding: Pooled OR 1.54 (95% CI 1.09 to 2.18) for cardiovascular events, but the effect split sharply by funding: non-industry trials OR 2.06 vs industry-funded trials OR 0.89 (p for interaction 0.03).
Limit: No included trial was designed to measure cardiovascular events; events were harvested from adverse-event reports with inconsistent definitions. A contemporaneous meta-analysis by Corona et al. (75 studies) found no cardiovascular risk (OR 1.07).
A small 2010 randomized trial in frail older men (Basaria et al., the TOM trial) had also been stopped early for excess cardiovascular events, and it formed part of the background signal, though it was not one of the three studies the FDA action rested on.
What the warning did to prescribing
Baillargeon and colleagues tracked nearly 10 million commercially insured men in JAMA (2018). Testosterone use had climbed from 0.52% in 2002 to 3.20% in 2013, then fell to 1.67% by 2016. The relative decrease from 2013 to 2016 was 48% in established users and 62% in new users. The authors’ own words: “The steepest decrease coincided with 2 published reports of testosterone-associated adverse cardiovascular events and an FDA communication.” A VA study over the same period found a 40% decrease.
Testosterone use among commercially insured US men ≥30, 2002 to 2016
All users: 0.52% (2002) → 3.20% (2013) → 1.67% (2016). Source: Baillargeon et al., JAMA 2018;320:200 to 202, Clinformatics Data Mart, 9,962,538 men. Commercially insured (employed) men, not generalisable to retired or Medicare populations. Testosterone use had also tripled from 2001 to 2011, mostly in men without a clear indication, so part of the fall was likely correction of overprescribing, not just undertreatment.
That last point matters, and honest writing about this topic has to hold both halves of it. Some of the prescribing that disappeared after 2013 should never have happened, the pre-2013 boom was driven substantially by men without a clear indication, in the era of “low T” advertising. And some of the men who lost access, or never got assessed, had the real disease. A blunt warning cannot tell those two groups apart. Clinicians, understandably, resolved the ambiguity by saying no more often, to everyone.
What TRAVERSE actually showed
The trial the FDA committee asked for in 2014 arrived in 2023. TRAVERSE (Lincoff et al., New England Journal of Medicine 2023) was the first adequately powered randomized cardiovascular safety trial of testosterone: 5,246 men aged 45 to 80, at 316 US sites, each with symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and either established cardiovascular disease or high cardiovascular risk. Men were randomized to daily 1.62% testosterone gel, dose adjusted to keep levels at 350 to 750 ng/dL, or matching placebo. Mean treatment duration was 21.7 months; mean follow-up was 33.0 months.
TRAVERSE: the primary result
In plain terms: in this population, at physiological doses, testosterone did not increase major cardiovascular events versus placebo. Noninferiority is not superiority. TRAVERSE did not show testosterone prevents events.
What it showed
- No increase in the primary MACE composite over ~3 years of follow-up in men with confirmed hypogonadism and high cardiovascular risk.
- Similar results in sensitivity analyses censoring at treatment discontinuation, and for the secondary composite including coronary revascularization.
- Enough reassurance that on 28 February 2025 the FDA removed the boxed-warning language on increased cardiovascular risk from all testosterone labels and added the TRAVERSE results to them.
What it did not show
- Secondary signals: higher incidence on testosterone of atrial fibrillation, acute kidney injury and pulmonary embolism (stated in the abstract without numbers; precise percentages circulating in secondary summaries were not verified against the NEJM full text for this article).
- Long-term safety beyond ~3 years; safety of injections (gel only); safety at supraphysiological, bodybuilding doses; safety in men without confirmed hypogonadism.
- Efficacy for energy, vitality or cognition. It was a safety trial, not an efficacy trial for those outcomes. Prostate-cancer numbers were too few to prove equivalence.
The limitations are real, too
A widely cited critique in JACC Advances (2023), an opinion piece, and worth reading as one, makes points any honest summary should carry: about 61% of participants discontinued their gel or placebo, so much of the follow-up happened off treatment, diluting any true difference in an intention-to-treat analysis; roughly 18% were lost to follow-up; achieved testosterone levels hovered near the bottom of the 350 to 750 ng/dL target (men started at a mean of 227 ng/dL and rose only ~148 ng/dL at 12 months); the trial enrolled 5,246 of a planned ~6,000 men; it was funded by AbbVie and other manufacturers; and men with recent MI or stroke or uncontrolled heart failure, the highest-risk subgroup, were excluded.
The accurate framing, then, is not “case closed.” It is: the best randomized evidence available excludes a large increase in major cardiovascular events over about three years, at physiological doses, in confirmed hypogonadism, and leaves the secondary signals open.
And note what the FDA did not do in February 2025. It retained the limitation of use for age-related hypogonadism. It added a blood-pressure warning, after ambulatory monitoring studies confirmed a class-wide rise in blood pressure. Testosterone remains Schedule III. The label change is not a recommendation to prescribe, nor a declaration of safety for everyone. One specific warning came off; another went on. (Reports in 2026 secondary sources that HHS/FDA has requested further changes, removing the age-related limitation and narrowing the prostate contraindication, describe a request, not a completed change, and were not verified on an FDA primary page for this article.)
Why primary care still hesitates
If the heart question has been substantially answered, why does the hesitation persist? Because the cardiovascular scare was only ever one layer of it. Several real frictions stack up at once. Some are documented. Some are not. It helps to keep the two apart.
⚠ An honesty note on the evidence for this section
No quantitative US survey of primary-care physicians’ attitudes toward testosterone prescribing was found in the research for this article. Reasons such as “minimal hormone training in residency” “fear of litigation or board action” and “prior-authorization burden” appear repeatedly in clinic and trade commentary, but no curriculum study, malpractice dataset or payer-policy source was found to verify them. They are presented below as commentary-level claims, plausible, widely repeated, and not survey-established fact.
The one peer-reviewed attitudinal study found is British, qualitative and small: interviews with 20 men (aged 45 to 62), 30 GPs and 10 endocrinologists, published in the Journal of Men’s Health in 2024 and commissioned by Besins Healthcare UK. Its findings are recognisable on either side of the Atlantic. Many GPs were unaware of the full range of testosterone-deficiency symptoms and did not think to check testosterone for non-specific complaints like fatigue and low energy, which were attributed to aging or work stress. Many lacked confidence in managing the condition and wanted standardized, guideline-based care. Stigma, embarrassment and “machismo” inhibited men from raising symptoms at all, and limited consultation time blocked the longer conversation. Endocrinologists, for their part, believed many referred men could be managed appropriately in primary care. Small, qualitative and industry-funded, but it points to knowledge gaps, low confidence, stigma and time pressure, not to a single cause.
The documented frictions
A diagnosis that takes work
Guideline diagnosis requires symptoms plus two early-morning fasting measurements, then LH/FSH, PSA and haematocrit, then a search for the cause, depression, hypothyroidism, sleep apnoea, obesity, opioids and pituitary disease can all sit behind the same complaints. A single low number is not a diagnosis, and ruling the mimics out is real work in a short visit.
A monitoring burden that never ends
Both major guidelines require baseline and ongoing monitoring of testosterone, haematocrit and prostate risk (details in the next section). That is a standing obligation, repeat labs, dose decisions, stop rules, attached to every prescription, indefinitely.
Fertility cuts the other way
Exogenous testosterone suppresses LH and FSH and with them sperm production. Both guidelines advise against starting it in men planning fertility in the near term; the AUA states it should not be prescribed to men currently trying to conceive. In younger men, hesitation is often the guideline working as intended.
Controlled-substance gravity
Schedule III status brings DEA registration, legitimate-medical-purpose documentation and diversion concern to every script. The regulatory facts are established; how heavily they weigh on individual clinicians’ decisions is inferred, not surveyed.
Training, liability and paperwork
Clinic commentary routinely cites minimal hormone training, fear of liability, prior-authorization fights and 15-minute visit economics. Each is plausible; none was verified against a primary source in this research. Treat them as the profession’s folklore until someone surveys it properly.
Guilt by association
A GP who prescribes testosterone risks being read as practicing “low-T clinic” medicine, because, as the next sections show, a visible part of that market prescribes without diagnosis, monitoring or thresholds. No survey quantifies the reputational effect, but the overprescribing it reacts to is documented.
Stack those together and “no” becomes the path of least resistance: a safety scare that has been superseded but is still seared in, a genuinely demanding diagnostic and monitoring protocol, a controlled-substance framework, and a cultural association with doping and anti-aging marketing. Not because the doctor has read TRAVERSE and rejected it. Often because the doctor trained during the warning years, never built the monitoring workflow, and has a waiting room full of problems that come with fewer questions attached.
What the guidelines actually say
Here is the part that surprises patients most: the guidelines are not against testosterone. The Endocrine Society (Bhasin et al., 2018), the American Urological Association (Mulhall et al., 2018) and, most narrowly, the American College of Physicians (2020) all describe a legitimate treatment for a defined condition. What they are against is treating a marketing category. “Low T” as advertised, fatigue, low energy, weight gain and fading vitality in aging men with borderline or unmeasured levels, is not the diagnosis any of them recognizes.
Endocrine Society: Bhasin et al., J Clin Endocrinol Metab 2018
- Diagnose only in men with symptoms/signs consistent with testosterone deficiency and unequivocally, consistently low serum testosterone.
- First test: fasting morning total testosterone with an accurate assay, then confirm by repeating it. Add free testosterone (equilibrium dialysis or accurate formula) when total T is near the lower limit or SHBG is altered. Then evaluate the cause.
- Treat symptomatic deficiency after discussing benefits, risks and monitoring, shared decision-making, aiming for mid-normal concentrations.
- Against routine screening of the general population, and against routinely prescribing to all men ≥65.
- Do not start with: plans for near-term fertility; breast or prostate cancer; palpable prostate nodule; PSA >4 ng/mL (>3 if at increased risk) without urological evaluation; elevated haematocrit; untreated severe sleep apnoea; severe lower urinary tract symptoms; uncontrolled heart failure; MI or stroke within 6 months; thrombophilia.
- Monitor: symptoms, adverse effects and compliance; serum testosterone and haematocrit; prostate-cancer risk during the first year.
Full text detail beyond the published abstract (exact monitoring intervals, haematocrit thresholds) is widely summarized secondhand; figures not in the abstract were not treated as verified for this article.
American Urological Association: Mulhall et al., J Urol 2018 · 31 recommendations
- Total testosterone <300 ng/dL is a reasonable cut-off (Moderate Recommendation, Grade B).
- Diagnosis only after two total testosterone measurements on separate occasions, both early morning (Strong, Grade A), and only when low levels combine with symptoms or signs.
- In men with low T, measure LH (Strong, Grade A); add prolactin if LH is low or low normal.
- Tell patients low testosterone is a risk factor for cardiovascular disease; the 2018 guideline (pre-TRAVERSE) could not say definitively whether therapy raises or lowers that risk.
- Do not prescribe exogenous testosterone to men currently trying to conceive; evaluate fertility interest before treatment.
- On therapy: measure testosterone every 6 to 12 months; measure hemoglobin/haematocrit before starting and counsel on polycythaemia risk; PSA in men over 40 before starting; discuss stopping at 3 to 6 months if levels normalize but symptoms do not improve.
American College of Physicians: Qaseem et al., Ann Intern Med 2020
- The guideline most primary care doctors actually work under, endorsed by the American Academy of Family Physicians, and the narrowest of the three.
- For age-related low testosterone, discuss treatment only when sexual dysfunction is present, to improve sexual function.
- Re-evaluate within 12 months and stop if sexual function does not improve.
- Do not initiate testosterone to improve energy, vitality, physical function or cognition, the evidence does not support it.
- Considers intramuscular over transdermal formulations on cost grounds.
Read together, the three guidelines explain a lot of “reluctance” that is actually compliance: a man asking for testosterone for energy and vitality, without sexual symptoms and without two low morning levels, is asking for something his own doctor’s guideline says not to do.
The diagnosis, step by step
What a guideline-concordant work-up actually looks like, the standard a prescription should be measured against:
Symptoms firstConsistent symptoms or signs of testosterone deficiency, not a number looking for a patient, and not fatigue alone without the rest of the picture.
Two early-morning fasting levelsTotal testosterone measured on two separate occasions, both early morning and fasting, with a reliable assay, below the cut-off both times (AUA: <300 ng/dL as a reasonable threshold).
Find the causeLH (and prolactin if LH is low), plus a search for reversible drivers, obesity, diabetes, opioids, sleep apnoea, pituitary disease, before replacing anything.
Screen the contraindicationsFertility plans, prostate risk (PSA, examination), haematocrit, sleep apnoea, heart failure, recent MI or stroke, thrombophilia.
Treat to mid-normal, and monitorShared decision-making, a mid-normal target (not an enhancement target), then scheduled testosterone, haematocrit and prostate monitoring, with a willingness to stop if symptoms do not improve.
Where the caution is justified
A piece arguing that testosterone is medicine’s black sheep would be dishonest if it pretended the wariness has no basis. Some of it is the correct clinical response to a drug with real effects beyond the one being treated.
Erythrocytosis: the most consistent risk
Testosterone thickens the blood. A systematic review commissioned for the Endocrine Society guideline found testosterone increased the risk of haematocrit above 54% (RR 8.14, 95% CI 1.87 to 35.40); in the T4DM trial of injected testosterone undecanoate, haematocrit >54% occurred in 22% on testosterone vs 1% on placebo. This is why haematocrit monitoring is not bureaucratic decoration. (Figures via secondary summary of Ponce et al., JCEM 2018.)
Fertility suppression
Exogenous testosterone suppresses LH and FSH, lowers intratesticular testosterone and reduces, sometimes abolishes, sperm production. Recovery takes months to years and is not guaranteed. Prescribing it to a man who wants children, without that conversation, is a harm, full stop.
Prostate: monitoring, not panic
Neither guideline finds definitive evidence that testosterone causes prostate cancer, and TRAVERSE found no difference, with too few cancers to prove equivalence. But PSA rises slightly more on treatment, and active prostate cancer remains a contraindication. Monitoring is mandatory precisely because the question is managed, not settled.
Sleep apnoea & blood pressure
Untreated severe obstructive sleep apnoea is a guideline contraindication to starting, because testosterone can worsen it. And the FDA’s February 2025 action added a blood-pressure warning on ambulatory-monitoring evidence even as it removed the cardiovascular boxed warning. “The warning came off” is only half of that headline.
And the low-T clinic problem is real
The strongest evidence that some caution is warranted comes from the sellers, not the sceptics. In a secret-shopper study published in JAMA Internal Medicine (Dubin et al., 2022), researchers presented to seven direct-to-consumer testosterone platforms as a 34-year-old man with normal testosterone who wanted children. Six of the seven offered him testosterone anyway. Only one of seven asked about recent cardiovascular events or desire for fertility; six of seven had no testosterone threshold at all; half quoted a treatment target above 1,000 ng/dL, roughly double the mid-normal aim the guidelines describe.
The pattern repeats at scale. A 2026 global analysis of 253 websites offering testosterone prescriptions found 9.9% prescribed for men with normal testosterone, 20.6% claimed testosterone reduces cardiovascular risk, and 9.9% marketed anti-aging effects, with US clinics the worst performers. And a single-center chart review presented at ENDO 2026, conference data, not yet peer reviewed, so weigh it accordingly, found that of 200 men prescribed testosterone between 2020 and 2025, only 12% had received a guideline-concordant evaluation: two low morning levels, LH/FSH, and no contraindications. A quarter of the prescriptions followed a patient request.
That is the environment a primary care doctor is looking at when a patient arrives asking for testosterone by name. The refusal is sometimes aimed at the man in the room. Often it is aimed at the market behind him.
The line worth holding
Strip the history away and the evidence supports a clear, narrow position. Treating symptomatic, confirmed hypogonadism, two low morning levels plus symptoms, cause investigated, no contraindications, to mid-normal levels, with monitoring, carries the reassurance of a 5,246-man randomized trial on major cardiovascular events over about three years. The evidence does not support testosterone for energy, vitality or cognition alone; at supraphysiological targets; without baseline labs; in men with normal levels who want children; or as a substitute for asking why the level is low in the first place.
The strongest version of the doctor’s case
“I am not against testosterone. I am against this testosterone, prescribed without a diagnosis, without monitoring, at enhancement doses, by a clinic that profits from saying yes.”
The strongest version of the patient’s case
“I do meet the guideline criteria, and I am being refused on the basis of a 2013 scare that a 5,246-man randomized trial and a 2025 FDA label change have superseded.”
Both of those people are right about the case they are describing. The failure happens when they are describing different cases and talking past each other, when a blanket “we don’t do testosterone here” meets a man who has done everything the guidelines ask, or when a legitimate prescription is expected to behave like the enhancement protocol a clinic advertised on a podcast.
Testosterone earned its black-sheep status honestly, in stadiums and in strip-mall clinics, long before it reached the exam room. But a hormone is not its worst users. The drug synthesized in 1935 for men whose bodies could not make enough of it is still that drug. The task for primary care is not to rehabilitate its reputation or to keep punishing it, it is the duller, harder work the guidelines already describe: measure twice, find the cause, treat the deficiency, monitor the man. Do that, and testosterone stops being the black sheep. It becomes what thyroid hormone got to be all along, just another hormone, replaced properly.
Open questions this article will not pretend are closed
- No quantitative US survey of primary-care attitudes toward testosterone was found. The training, liability and prior-authorization explanations remain commentary level until one exists.
- TRAVERSE’s secondary signals (atrial fibrillation, acute kidney injury, pulmonary embolism) are stated without numbers in the trial abstract; precise percentages in circulation come from secondary summaries.
- Whether the reported 2026 request to remove the age-related limitation of use becomes a completed FDA label change is unresolved, as of the sources checked, it is a request, not a change.
- Long-term safety beyond ~3 years, injectable formulations, and men at the very highest cardiovascular risk remain outside what TRAVERSE tested.
Follow @dr.francisco_md for the Saturday hormone-health series: protein after 40, peptides, estrogen in men, visceral fat and alcohol are next in the queue.
References
- FDA. FDA issues class-wide labeling changes for testosterone products (28 Feb 2025), TRAVERSE results added; cardiovascular boxed warning removed; age-related limitation retained; blood-pressure warning added. fda.gov
- FDA Drug Safety Communication (3 Mar 2015): label changes, approved uses clarified; possible increased risk of heart attack and stroke. drugs.com
- Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med. 2023;389(2):107 to 117. doi:10.1056/NEJMoa2215025. PubMed 37326322
- Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715 to 1744. PubMed 29562364
- Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423 to 432. PubMed 29601923
- Qaseem A, et al. Testosterone treatment in adult men with age-related low testosterone: ACP clinical guideline. Ann Intern Med. 2020. acponline.org
- Vigen R, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829 to 1836. PubMed 24193080
- Finkle WD, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. PMC3905977
- Xu L, et al. Testosterone therapy and cardiovascular events among men: systematic review and meta-analysis. BMC Med. 2013;11:108. PMC3648456
- Baillargeon J, et al. Testosterone prescribing in the United States, 2002 to 2016. JAMA. 2018;320:200 to 202. jamanetwork.com
- Dubin JM, et al. Guideline-discordant care among direct-to-consumer testosterone therapy platforms. JAMA Intern Med. 2022;182(12):1321 to 1323. medicalxpress.com summary
- Testosterone Replacement: Is it the TRAVERSE Trial or a Travesty? JACC Advances. 2023;2(10):100742. PMC11198716
- Barriers to diagnosis and accessing effective treatment and support for testosterone deficiency. J Men’s Health. 2024. doi:10.22514/jomh.2024.001. pharmacymagazine.co.uk summary
- Anabolic Steroids Control Act of 1990, Schedule III placement; statutory definition at 21 U.S.C. §802. en.wikipedia.org; DEA Schedule III status summary: legalclarity.org
- Global analysis of websites offering testosterone prescriptions. J Clin Endocrinol Metab. 2026;111(6):1651. academic.oup.com
- Testosterone prescribing often ignores guidelines, single-centre review presented at ENDO 2026 (conference report, not peer-reviewed). medscape.com
Research verified 15 November 2026. Where a figure rests on a secondary summary rather than a primary text, the article says so at the point of use.



